Literature DB >> 34964815

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.

.   

Abstract

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
© 2021 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2022        PMID: 34964815     DOI: 10.2337/dc22-S010

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


  32 in total

Review 1.  Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis.

Authors:  Xiao Liu; Ziqi Tan; Yuna Huang; Huilei Zhao; Menglu Liu; Peng Yu; Jianyong Ma; Yujie Zhao; Wengen Zhu; Jingfeng Wang
Journal:  Cardiovasc Diabetol       Date:  2022-07-01       Impact factor: 8.949

2.  Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary.

Authors:  John Anderson; James R Gavin; Davida F Kruger; Eden Miller
Journal:  Clin Diabetes       Date:  2022

Review 3.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse
Journal:  Diabetologia       Date:  2022-09-24       Impact factor: 10.460

Review 4.  Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.

Authors:  Agnieszka Przezak; Weronika Bielka; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

5.  Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002-2019).

Authors:  Aimin Yang; Hongjiang Wu; Eric S H Lau; Xinge Zhang; Mai Shi; Baoqi Fan; Ronald C W Ma; Alice P S Kong; Andrea O Y Luk; Juliana C N Chan; Elaine Chow
Journal:  Lancet Reg Health West Pac       Date:  2022-06-24

Review 6.  Diabetes: how to manage cardiovascular risk in secondary prevention patients.

Authors:  Sarah L Anderson; Joel C Marrs
Journal:  Drugs Context       Date:  2022-06-14

Review 7.  NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes.

Authors:  Marcus Vinicius Bolivar Malachias; Magnus Olof Wijkman; Marcello Casaccia Bertoluci
Journal:  Diabetol Metab Syndr       Date:  2022-05-03       Impact factor: 5.395

Review 8.  Diabetes and restenosis.

Authors:  Scott Wilson; Pasquale Mone; Urna Kansakar; Stanislovas S Jankauskas; Kwame Donkor; Ayobami Adebayo; Fahimeh Varzideh; Michael Eacobacci; Jessica Gambardella; Angela Lombardi; Gaetano Santulli
Journal:  Cardiovasc Diabetol       Date:  2022-02-14       Impact factor: 9.951

Review 9.  An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.

Authors:  Teresa Salvatore; Raffaele Galiero; Alfredo Caturano; Luca Rinaldi; Anna Di Martino; Gaetana Albanese; Jessica Di Salvo; Raffaella Epifani; Raffaele Marfella; Giovanni Docimo; Miriam Lettieri; Celestino Sardu; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

Review 10.  Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do Not Tell, Yet).

Authors:  Manuela Casula; Alberico Luigi Catapano; Paolo Magni
Journal:  Nutrients       Date:  2022-01-30       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.